Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 2/20 | 0.44 |
| ▸ | PLAU | P00749 | 2/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.44 |
| ▸ | PPARG | P37231 | 6/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.41 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL221135 | 0.81 | THRB (0.50) | PLGPLAUHDAC8HDAC6HDAC1 | |
| SCHEMBL221602 | 0.79 | EPHX2 (0.51) | HDAC8HDAC6HDAC1HDAC2HDAC3 | |
| SCHEMBL220311 | 0.78 | PLAU (0.52) | PLGPLAUHDAC8HDAC6HDAC1 | |
| SCHEMBL218188 | 0.76 | PLG (0.49) | PLGPLAUHDAC8HDAC6HDAC1 | |
| SCHEMBL218880 | 0.75 | OPRM1 (0.48) | PLGPLAUHDAC8HDAC6HDAC1 | |
| SCHEMBL219825 | 0.75 | PLG (0.48) | PLGPLAUHDAC8HDAC6HDAC1 | |
| SCHEMBL220832 | 0.75 | PLG (0.48) | PLGPLAUHDAC8HDAC6HDAC1 | |
| SCHEMBL221760 | 0.74 | PLA2G4A (0.49) | PLGPLAUHDAC8HDAC6HDAC1 | |
| SCHEMBL3891994 | 0.74 | PLAU (0.60) | PLGPLAUHDAC8HDAC6HDAC1 | |
| SCHEMBL222138 | 0.73 | OPRM1 (0.50) | PLGPLAUHDAC8HDAC6HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088800-B2 | 4-(5-aminomethyl)-indole-1-ylmethyl)-benzamide derivatives and related compounds as opioid receptor antagonists for the treatment of obesity | ELI LILLY AND COMPANY (US) | 2012-01-03 | — | — | US | claimed |
| EP-1751103-B1 | 4-(5-(AMINOMETHYL)-INDOLE-1-YLMETHYL)-BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS OPIOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OBESITY | LILLY CO ELI (US) | 2009-01-14 | — | — | EP | claimed |
| US-20070155793-A1 | 4-(5-AMINOMETHYL)-INDOLE-1-YLMETHYL)-BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS OPIOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OBESITY | ELI LILLY AND COMPANY | 2007-07-05 | — | — | US | claimed |
| EP-1751103-A1 | 4-(5-(AMINOMETHYL)-INDOLE-1-YLMETHYL)-BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS OPIOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OBESITY | ELI LILLY AND COMPANY (US) | 2007-02-14 | — | — | EP | claimed |
| WO-2005090303-A1 | 4- (5- (AMINOMETHYL) -INDOLE-1-YLMETHYL) -BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS OPIOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OBESITY | ELI LILLY AND COMPANY (US) | 2005-09-29 | — | — | WO | claimed |
| US-8088800-B2 | 4-(5-aminomethyl)-indole-1-ylmethyl)-benzamide derivatives and related compounds as opioid receptor antagonists for the treatment of obesity | ELI LILLY AND COMPANY (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088800-B2 | 4-(5-aminomethyl)-indole-1-ylmethyl)-benzamide derivatives and related compounds as opioid receptor antagonists for the treatment of obesity | ELI LILLY AND COMPANY (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088800-B2 | 4-(5-aminomethyl)-indole-1-ylmethyl)-benzamide derivatives and related compounds as opioid receptor antagonists for the treatment of obesity | ELI LILLY AND COMPANY (US) | 2012-01-03 | — | — | US | disclosed |
| EP-1751103-B1 | 4-(5-(AMINOMETHYL)-INDOLE-1-YLMETHYL)-BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS OPIOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OBESITY | LILLY CO ELI (US) | 2009-01-14 | — | — | EP | disclosed |
| EP-1751103-B1 | 4-(5-(AMINOMETHYL)-INDOLE-1-YLMETHYL)-BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS OPIOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OBESITY | LILLY CO ELI (US) | 2009-01-14 | — | — | EP | disclosed |
| US-20070155793-A1 | 4-(5-AMINOMETHYL)-INDOLE-1-YLMETHYL)-BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS OPIOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OBESITY | ELI LILLY AND COMPANY | 2007-07-05 | — | — | US | disclosed |
| US-20070155793-A1 | 4-(5-AMINOMETHYL)-INDOLE-1-YLMETHYL)-BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS OPIOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OBESITY | ELI LILLY AND COMPANY | 2007-07-05 | — | — | US | disclosed |
| US-20070155793-A1 | 4-(5-AMINOMETHYL)-INDOLE-1-YLMETHYL)-BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS OPIOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OBESITY | ELI LILLY AND COMPANY | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155793-A1 | 4-(5-AMINOMETHYL)-INDOLE-1-YLMETHYL)-BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS OPIOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OBESITY | OPRM1, OPRD1, OPRK1 | PLG 4114/4885PLAU 4230/4885HDAC8 676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.